Elevated serum annexin A1 as potential diagnostic marker for lung cancer: A retrospective case-control study

American Journal of Translational Research

Volumn 6, Issue 5, 2014, Pages 558-569

  Rong, Biaoxue ^a   Zhao, Chongchong ^b   Liu, Hua ^c   Ming, Zongjuan ^a   Cai, Xiguang ^c   Gao, Wenlong ^b   Yang, Shuanying ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

^c GANSU PROVINCIAL HOSPITAL   (China)

Author keywords

annexin A1; biomarker; diagnosis; Lung cancer; serum

Indexed keywords

LIPOCORTIN 1; MESSENGER RNA;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UPREGULATION; WESTERN BLOTTING;

EID: 84908067159     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sawyers CL. The cancer biomarker problem. Nature 2008; 452: 548-552.
2. Kim B, Lee HJ, Choi HY, Shin Y, Nam S, Seo G, Son DS, Jo J, Kim J, Lee J, Kim K and Lee S. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 2007; 67: 7431-7438.
3. Tufman A and Huber RM. Biological markers in lung cancer: A clinician’s perspective. Cancer Biomark 2010; 6: 123-135.
4. Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W and Min Z. Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res 2012; 31: 70.
5. Lim LHK and Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J 2007; 21: 968-975.
6. Bai XF, Ni XG, Zhao P, Liu SM, Wang HX, Guo B, Zhou LP, Liu F, Zhang JS and Wang K. Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol 2004; 10: 1466-1470.
7. Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, Itano T, Matsui H, Arima K, Shirai M, Maeba T, Sogawa K, Konishi R, Taniguchi K, Hatanaka Y, Hatase O and Nishioka M. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 1996; 24: 72-81.
8. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714.
9. Fiore E, Campani D, Muller I, Belardi V, Giustarini E, Rossi G, Pinchera A and Giani C. IGF-II mRNA expression in breast cancer: predictive value and relationship to other prognostic factors. Int J Biol Markers 2010; 25: 150-156.
10. Hanley JA. Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 1989; 29: 307-335.
11. Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, Guarnera MA, Li R, Cai L, Zhan M and Jiang F. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011; 11: 374.
12. Cedres S, Nunez I, Longo M, Martinez P, Checa E, Torrejon D and Felip E. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2011; 12: 172-179.
13. Yu D, Du K, Liu T and Chen G. Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients. Int J Mol Sci 2013; 14: 11145-11156.
14. Sung HJ and Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 2008; 41: 615-625.
15. Sato Y, Kumamoto K, Saito K, Okayama H, Hayase S, Kofunato Y, Miyamoto K, Nakamura I, Ohki S, Koyama Y and Takenoshita S. Up-regulated Annexin A1 expression in gastrointestinal cancer is associated with cancer invasion and lymph node metastasis. Exp Ther Med 2011; 2: 239-243.
16. Li CF, Shen KH, Huang LC, Huang HY, Wang YH and Wu TF. Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma. Pathology 2010; 42: 43-49.
17. Su N, Xu XY, Chen H, Gao WC, Ruan CP, Wang Q and Sun YP. Increased expression of annexin A1 is correlated with K-ras mutation in colorectal cancer. Tohoku J Exp Med 2010; 222: 243-250.
18. Liu YF, Zhang PF, Li MY, Li QQ and Chen ZC. Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma. Clin Exp Metastasis 2011; 28: 413-425.
19. Cloez-Tayarani I and Fillion G. The in situ hybridization and immunocytochemistry techniques for characterization of cells expressing specific mRNAs in paraffin-embedded brains. Brain Res Brain Res Protoc 1997; 1: 195-202.
20. Schnitt SJ. Breast cancer in the 21st century: neu opportunities and neu challenges. Mod Pathol 2001; 14: 213-218.
21. Hanada S, Nishiyama N, Mizuguchi S, Yamano S, Kakehashi A, Wei M, Inoue H, Komatsu H, Chung K, Suehiro S and Wanibuchi H. Clinicopathological significance of combined analysis of cytokeratin19 expression and preoperative serum CYFRA21-1 levels in human lung squamous cell carcinoma. Osaka City Med J 2013; 59: 35-44.
22. Cao X, Zhang L, Feng GR, Yang J, Wang RY, Li J, Zheng XM and Han YJ. Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma. J Transl Med 2012; 10: 197.